이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

SD Biosensor 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Hyo Keun Lee

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	데이터 없음

최근 관리 업데이트

업데이트 없음

Recent updates

CEO

Hyo Keun Lee

no data

테뉴어

Hyo Keun Lee is Vice Chairman and Chief Executive Officer of SD BioSensor, Inc.

SD Biosensor 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Recent updates

What SD Biosensor, Inc's (KRX:137310) 25% Share Price Gain Is Not Telling You

Second quarter 2024 earnings released: ₩153 loss per share (vs ₩806 loss in 2Q 2023)

Would SD Biosensor (KRX:137310) Be Better Off With Less Debt?

Insufficient Growth At SD Biosensor, Inc (KRX:137310) Hampers Share Price

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: ₩91.00 loss per share (vs ₩2,177 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient Growth At SD Biosensor, Inc (KRX:137310) Hampers Share Price

Upcoming dividend of ₩290 per share at 8.7% yield

Third quarter 2023 earnings released: ₩552 loss per share (vs ₩4,166 profit in 3Q 2022)

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 23%

New minor risk - Share price stability

SD Biosensor, Inc has completed a Follow-on Equity Offering in the amount of KRW 227.8 billion.

Upcoming dividend of ₩700 per share at 7.5% yield

Now 21% undervalued after recent price drop

SD Biosensor, Inc. Proposes Discontuation of Use and Disposal of Specific Pilot COVID-19 At-Home Tests in the United States Due to Microbial Contamination in the Liquid Disposal Solution

Full year 2022 earnings: EPS and revenues miss analyst expectations

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners completed the acquisition of Meridian Bioscience, Inc. (NasdaqGS:VIVO) from Impactive Capital LP, BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc, Royce & Associates, LP and others.

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Price target decreased to ₩56,500

SD BioSensor, Inc (KOSE:A137310) (SDB) and SJL Partners (collectively, the "Consortium") entered into a definitive merger agreement to acquire Meridian Bioscience, Inc. (NasdaqGS:VIVO) for $1.5 billion.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Consensus revenue estimates increase by 17%

SD BioSensor, Inc (KOSE:A137310) agreed to acquire Relab S.R.L. for KRW 61.9 billion.

SD BioSensor, Inc (KOSE:A137310) acquired bestbion dx - Diagnostische Produkte und Beratung GmbH for KRW 16 billion.

Investor sentiment deteriorated over the past week

CEO

테뉴어